Choose Your Country or Region

Anti-Phospho-ERK1/ERK2 (T185/Y187) Rabbit Antibody [G10H2]

Catalog No.: F3945

Application: Reactivity: Human, Rat, Dog

Usage Information

Dilution
WB1:1000 IHC1:200 IF1:200 CHIP1:1000

Application
WB, IHC, IF, ChIP, ELISA

Reactivity
Human, Rat, Dog

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
~42 kDa-44 kDa

Positive Control	Human lung carcinoma; Hela (EGF, 100 ng/ml, 10 min); Jurkat (PMA, 200 nM, 30min); NIH/3T3 (EGF, 100 ng/ml, 10 min); NRK (treated with TPA); MDCK (treated with TPA); A549 (EGF, 200 ng/ml, 10 min)
Negative Control	Hela; Jurkat

Datasheet & SDS

Biological Description

Specificity
Phospho-ERK1/ERK2 (Thr185, Tyr187) Rabbit mAb detects endogenous levels of ERK1/ERK2 protein only when phosphorylated at Thr185, Tyr187 respectively.

Clone
G10H2

Synonym(s)
ERK-1; ERK-2; erk1 erk2; ERK1b; ERT1; ERT2; Extracellular signal-regulated kinase 1; Extracellular signal-regulated kinase 2; extracellular signal-related kinase 1; extracellular-signal-regulated kinase 2; Insulin-stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase 3; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3

Background
Phospho-ERK1/ERK2 (Thr185, Tyr187) refers to the activated forms of the extracellular signal-regulated kinases ERK1 and ERK2, which are ubiquitously expressed serine/threonine kinases in the Ras-Raf-MEK-ERK MAPK signaling cascade. ERK1 (379 aa) and ERK2 (360 aa) contain unique N- and C-terminal extensions and a kinase insert domain that confer signaling specificity. Activation requires dual phosphorylation by MEK1/2 at a conserved threonine (Thr202 in ERK1/Thr185 in ERK2) and tyrosine (Tyr204 in ERK1/Tyr187 in ERK2) within the activation loop, enabling them to phosphorylate a broad spectrum of cytoplasmic and nuclear substrates, including transcription factors such as Elk-1, Ets, and c-Fos, thereby regulating proliferation, differentiation, survival, migration, and metabolism. Nuclear translocation of phospho-ERK1/2 triggers immediate early gene expression, and dysregulation of their activation is implicated in numerous diseases, particularly cancers driven by aberrant RAS or RAF signaling, making phospho-ERK1/2 critical biomarkers and therapeutic targets.

Background

Phospho-ERK1/ERK2 (Thr185, Tyr187) refers to the activated forms of the extracellular signal-regulated kinases ERK1 and ERK2, which are ubiquitously expressed serine/threonine kinases in the Ras-Raf-MEK-ERK MAPK signaling cascade. ERK1 (379 aa) and ERK2 (360 aa) contain unique N- and C-terminal extensions and a kinase insert domain that confer signaling specificity. Activation requires dual phosphorylation by MEK1/2 at a conserved threonine (Thr202 in ERK1/Thr185 in ERK2) and tyrosine (Tyr204 in ERK1/Tyr187 in ERK2) within the activation loop, enabling them to phosphorylate a broad spectrum of cytoplasmic and nuclear substrates, including transcription factors such as Elk-1, Ets, and c-Fos, thereby regulating proliferation, differentiation, survival, migration, and metabolism. Nuclear translocation of phospho-ERK1/2 triggers immediate early gene expression, and dysregulation of their activation is implicated in numerous diseases, particularly cancers driven by aberrant RAS or RAF signaling, making phospho-ERK1/2 critical biomarkers and therapeutic targets.

References
https://pubmed.ncbi.nlm.nih.gov/22569528/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%